Meeder Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-90
| Closed | -$5K | – | 1150 |
|
|
2022
Q3 | $5K | Sell |
90
-21
| -19% | -$1.17K | ﹤0.01% | 1552 |
|
|
2022
Q2 | $5K | Sell |
111
-22
| -17% | -$991 | ﹤0.01% | 1637 |
|
|
2022
Q1 | $9K | Buy |
+133
| New | +$9K | ﹤0.01% | 1576 |
|
|
2021
Q4 | – | Sell |
-106
| Closed | -$6K | – | 1524 |
|
|
2021
Q3 | $6K | Buy |
106
+11
| +12% | +$623 | ﹤0.01% | 1852 |
|
|
2021
Q2 | $4K | Sell |
95
-40
| -30% | -$1.68K | ﹤0.01% | 2009 |
|
|
2021
Q1 | $7K | Sell |
135
-9
| -6% | -$467 | ﹤0.01% | 1731 |
|
|
2020
Q4 | $6K | Buy |
144
+6
| +4% | +$250 | ﹤0.01% | 1140 |
|
|
2020
Q3 | $6K | Buy |
138
+108
| +360% | +$4.7K | ﹤0.01% | 1510 |
|
|
2020
Q2 | $2K | Buy |
+30
| New | +$2K | ﹤0.01% | 1757 |
|
|
2020
Q1 | – | Sell |
-127
| Closed | -$8K | – | 2373 |
|
|
2019
Q4 | $8K | Sell |
127
-223
| -64% | -$14K | ﹤0.01% | 1620 |
|
|
2019
Q3 | $21K | Sell |
350
-4,008
| -92% | -$240K | ﹤0.01% | 1289 |
|
|
2019
Q2 | $368K | Buy |
4,358
+3,140
| +258% | +$265K | 0.03% | 461 |
|
|
2019
Q1 | $117K | Sell |
1,218
-537
| -31% | -$51.6K | 0.01% | 658 |
|
|
2018
Q4 | $124K | Sell |
1,755
-102
| -5% | -$7.21K | 0.01% | 588 |
|
|
2018
Q3 | $159K | Sell |
1,857
-460
| -20% | -$39.4K | 0.01% | 536 |
|
|
2018
Q2 | $269K | Buy |
2,317
+1,280
| +123% | +$148K | 0.02% | 460 |
|
|
2018
Q1 | $85K | Sell |
1,037
-87
| -8% | -$7.13K | 0.01% | 579 |
|
|
2017
Q4 | $66K | Buy |
1,124
+174
| +18% | +$10.2K | 0.01% | 631 |
|
|
2017
Q3 | $45K | Buy |
950
+795
| +513% | +$37.7K | ﹤0.01% | 699 |
|
|
2017
Q2 | $6K | Buy |
155
+86
| +125% | +$3.33K | ﹤0.01% | 1139 |
|
|
2017
Q1 | $2K | Buy |
+69
| New | +$2K | ﹤0.01% | 1361 |
|